The global brain tumor therapeutics market was estimated at USD XX million in 2015 and is expected to reach USD XX million by 2021, growing at a CAGR of X% during the forecast period 2016 to 2021.
Brain tumor, also known as intracranial neoplasm, is the abnormal growth of cells from within the brain; brain tumor can be malignant and benign. The malignant tumors can be classified into primary and secondary. While primary tumors start within the brain, secondary tumors, also called as brain metastasis tumors, are those that spread from other body parts. There are different types of brain tumors that include glioma, meningioma, pituitary adenoma, schwannomas and medulloblastoma. As per the National Cancer Institute estimates, 23,770 new cases of brain tumor were diagnosed in 2016, in the United States itself. The statistics estimate that more than 4,000 children and teens were diagnosed with brain tumor. The National Cancer Institute, USA, states that at least 33.8% such patients survive for five years.
Market Dynamics – Brain Tumor Therapeutics
The key factors driving this market are -
The factors restraining the market are -
The market has been segmented based on the radiation therapy, chemotherapy, and targeted therapy. Chemotherapy includes drugs such as Carboplatin, Carmustine, Cisplatin, Cyclophosphamide, Etoposide, Irinotecan, Lomustine, Methotrexate, Procarbazine, Temozolomide and Vincristine and targeted therapy includes Avastin.
Geographically, the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America.
The key players in this market are -
What the Report Offers